the kennedy trust for rheumatology researchEstimated Valuation
£14.4m
Pomanda estimates the enterprise value of THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH at £14.4m based on a Turnover of £10.7m and 1.35x industry multiple (adjusted for size and gross margin).
the kennedy trust for rheumatology researchEstimated Valuation
£30m
Pomanda estimates the enterprise value of THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH at £30m based on an EBITDA of £4.8m and a 6.29x industry multiple (adjusted for size and gross margin).
the kennedy trust for rheumatology researchEstimated Valuation
£527.1m
Pomanda estimates the enterprise value of THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH at £527.1m based on Net Assets of £301.9m and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The Kennedy Trust For Rheumatology ResearchOverview
The Kennedy Trust For Rheumatology Research is a live company located in london, EC1M 6HR with a Companies House number of 00963832. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in October 1969, it's largest shareholder is
unknown.
The Kennedy Trust For Rheumatology Research is a mature,
mid sized company, Pomanda has estimated its turnover at
£10.7m with
declining
growth in recent years.
The Kennedy Trust For Rheumatology Research Health Check
Pomanda's financial health check has awarded The Kennedy Trust For Rheumatology Research a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
4 Strong
2 Regular
3 Weak
Size
annual sales of £10.7m, make it larger than the average company (£4.3m)
£10.7m - The Kennedy Trust For Rheumatology Research
£4.3m - Industry AVG
Growth
3 year (CAGR) sales growth of 0%, show it is growing at a slower rate (7.8%)
0% - The Kennedy Trust For Rheumatology Research
7.8% - Industry AVG
Production
with a gross margin of 49.8%, this company has a comparable cost of product (49.8%)
49.8% - The Kennedy Trust For Rheumatology Research
49.8% - Industry AVG
Profitability
an operating margin of 44.7% make it more profitable than the average company (2%)
44.7% - The Kennedy Trust For Rheumatology Research
2% - Industry AVG
Employees
with 5 employees, this is below the industry average (44)
5 - The Kennedy Trust For Rheumatology Research
44 - Industry AVG
Pay Structure
on an average salary of £56.2k, the company has an equivalent pay structure (£64.5k)
£56.2k - The Kennedy Trust For Rheumatology Research
£64.5k - Industry AVG
Efficiency
resulting in sales per employee of £2.1m, this is more efficient (£124.7k)
£2.1m - The Kennedy Trust For Rheumatology Research
£124.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - The Kennedy Trust For Rheumatology Research
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - The Kennedy Trust For Rheumatology Research
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - The Kennedy Trust For Rheumatology Research
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 6 weeks, this is less cash available to meet short term requirements (34 weeks)
6 weeks - The Kennedy Trust For Rheumatology Research
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 9.9%, this is a lower level of debt than the average (41.4%)
9.9% - The Kennedy Trust For Rheumatology Research
41.4% - Industry AVG
THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH financials
EXPORT
The Kennedy Trust For Rheumatology Research's latest turnover from September 2024 is £10.7 million and the company has net assets of £301.9 million. According to their latest financial statements, The Kennedy Trust For Rheumatology Research has 5 employees and maintains cash reserves of £1.7 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Turnover
10,657,000
8,903,000
8,718,000
10,801,000
8,805,000
11,137,000
21,155,000
32,939,000
37,282,000
28,401,000
37,022,000
29,435,000
88,618,000
45,189,000
55,650,000
62,622,000
Other Income Or Grants
Cost Of Sales
5,353,590
4,636,058
4,511,339
5,606,129
4,537,657
5,687,792
10,762,135
16,801,954
18,925,019
15,556,414
20,694,827
15,905,477
48,967,769
24,714,434
30,825,676
Gross Profit
5,303,410
4,266,942
4,206,661
5,194,871
4,267,343
5,449,208
10,392,865
16,137,046
18,356,981
12,844,586
16,327,173
13,529,523
39,650,231
20,474,566
24,824,324
Admin Expenses
541,560
12,875,388
3,011,079
-32,026,085
5,426,823
8,292,605
3,238,663
15,984,744
9,940,956
16,912,153
254,326
15,128,738
-26,774,914
25,678,896
-17,206,938
-47,202,654
Operating Profit
4,761,850
-8,608,446
1,195,582
37,220,956
-1,159,480
-2,843,397
7,154,202
152,302
8,416,025
-4,067,567
16,072,847
-1,599,215
66,425,145
-5,204,330
42,031,262
47,202,654
Interest Payable
Interest Receivable
Pre-Tax Profit
3,630,000
-8,524,000
1,013,000
30,151,000
-1,158,000
-2,825,000
5,814,000
131,000
6,739,000
-4,059,000
12,703,000
-1,583,000
50,521,000
-5,108,000
30,344,000
34,023,000
Tax
Profit After Tax
3,630,000
-8,524,000
1,013,000
30,151,000
-1,158,000
-2,825,000
5,814,000
131,000
6,739,000
-4,059,000
12,703,000
-1,583,000
50,521,000
-5,108,000
30,344,000
34,023,000
Dividends Paid
Retained Profit
3,630,000
-8,524,000
1,013,000
30,151,000
-1,158,000
-2,825,000
5,814,000
131,000
6,739,000
-4,059,000
12,703,000
-1,583,000
50,521,000
-5,108,000
30,344,000
34,023,000
Employee Costs
281,000
251,000
244,000
199,000
204,000
207,000
197,000
197,000
185,000
191,000
190,000
198,000
174,000
212,000
208,000
193,000
Number Of Employees
5
3
3
3
2
2
2
2
2
2
3
15
1
3
2
2
EBITDA*
4,762,850
-8,606,446
1,196,582
37,220,956
-1,159,480
-2,843,397
7,154,202
152,302
8,416,025
-4,067,567
16,072,847
-1,599,215
66,425,145
-5,204,330
42,031,262
47,202,654
* Earnings Before Interest, Tax, Depreciation and Amortisation
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Tangible Assets
1,000
2,000
4,000
Intangible Assets
Investments & Other
332,941,000
305,489,000
313,759,000
341,670,000
302,293,000
316,541,000
303,788,000
289,009,000
265,484,000
226,365,000
222,152,000
200,420,000
162,313,000
132,760,000
97,536,000
69,789,000
Debtors (Due After 1 year)
Total Fixed Assets
332,942,000
305,491,000
313,763,000
341,670,000
302,293,000
316,541,000
303,788,000
289,009,000
265,484,000
226,365,000
222,152,000
200,420,000
162,313,000
132,760,000
97,536,000
69,789,000
Stock & work in progress
Trade Debtors
4,285,000
7,817,000
5,916,000
8,003,000
11,555,000
11,651,000
9,958,000
Group Debtors
Misc Debtors
472,000
1,368,000
579,000
667,000
803,000
1,279,000
138,000
124,000
8,218,000
7,703,000
6,935,000
1,342,000
38,045,000
621,000
576,000
569,000
Cash
1,706,000
1,420,000
1,797,000
3,095,000
1,906,000
1,055,000
3,851,000
2,436,000
5,105,000
1,075,000
2,352,000
408,000
6,078,000
13,864,000
24,668,000
20,605,000
misc current assets
19,817,000
11,836,000
total current assets
2,178,000
2,788,000
2,376,000
3,762,000
2,709,000
2,334,000
28,091,000
22,213,000
13,323,000
8,778,000
9,287,000
7,666,000
52,126,000
26,040,000
36,895,000
31,132,000
total assets
335,120,000
308,279,000
316,139,000
345,432,000
305,002,000
318,875,000
331,879,000
311,222,000
278,807,000
235,143,000
231,439,000
208,086,000
214,439,000
158,800,000
134,431,000
100,921,000
Bank overdraft
Bank loan
Trade Creditors
202,000
444,000
539,000
1,312,000
2,717,000
5,921,000
5,091,000
4,884,000
7,834,000
5,431,000
4,952,000
6,807,000
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
13,429,000
14,109,000
10,355,000
9,280,000
9,261,000
10,210,000
33,747,000
6,943,000
5,505,000
7,297,000
11,779,000
14,679,000
32,471,000
22,187,000
5,591,000
4,468,000
total current liabilities
13,429,000
14,109,000
10,355,000
9,280,000
9,463,000
10,654,000
34,286,000
8,255,000
8,222,000
13,218,000
16,870,000
19,563,000
40,305,000
27,618,000
10,543,000
11,275,000
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
19,783,000
22,267,000
26,666,000
29,724,000
19,262,000
16,516,000
14,074,000
33,500,000
13,536,000
8,721,000
3,110,000
2,439,000
111,000
14,507,000
970,000
1,853,000
provisions
total long term liabilities
19,783,000
22,267,000
26,666,000
29,724,000
19,262,000
16,516,000
14,074,000
33,500,000
13,536,000
8,721,000
3,110,000
2,439,000
111,000
14,507,000
970,000
1,853,000
total liabilities
33,212,000
36,376,000
37,021,000
39,004,000
28,725,000
27,170,000
48,360,000
41,755,000
21,758,000
21,939,000
19,980,000
22,002,000
40,416,000
42,125,000
11,513,000
13,128,000
net assets
301,908,000
271,903,000
279,118,000
306,428,000
276,277,000
291,705,000
283,519,000
269,467,000
257,049,000
213,204,000
211,459,000
186,084,000
174,023,000
116,675,000
122,918,000
87,793,000
total shareholders funds
301,908,000
271,903,000
279,118,000
306,428,000
276,277,000
291,705,000
283,519,000
269,467,000
257,049,000
213,204,000
211,459,000
186,084,000
174,023,000
116,675,000
122,918,000
87,793,000
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Operating Activities
Operating Profit
4,761,850
-8,608,446
1,195,582
37,220,956
-1,159,480
-2,843,397
7,154,202
152,302
8,416,025
-4,067,567
16,072,847
-1,599,215
66,425,145
-5,204,330
42,031,262
47,202,654
Depreciation
1,000
2,000
1,000
Amortisation
Tax
Stock
Debtors
-896,000
789,000
-88,000
-136,000
-476,000
-3,144,000
-3,518,000
-277,000
515,000
768,000
-323,000
-38,790,000
33,872,000
-51,000
1,700,000
10,527,000
Creditors
-202,000
-242,000
-95,000
-773,000
-1,405,000
-3,204,000
830,000
207,000
-2,950,000
2,403,000
479,000
-1,855,000
6,807,000
Accruals and Deferred Income
-680,000
3,754,000
1,075,000
19,000
-949,000
-23,537,000
26,804,000
1,438,000
-1,792,000
-4,482,000
-2,900,000
-17,792,000
10,284,000
16,596,000
1,123,000
4,468,000
Deferred Taxes & Provisions
Cash flow from operations
4,978,850
-5,641,446
2,359,582
37,173,956
-1,874,480
-23,331,397
36,703,202
462,302
2,905,025
-8,487,567
13,702,847
16,448,785
45,240,145
11,921,670
39,599,262
47,950,654
Investing Activities
capital expenditure
-6,542,000
Change in Investments
27,452,000
-8,270,000
-27,911,000
39,377,000
-14,248,000
12,753,000
14,779,000
23,525,000
39,119,000
4,213,000
21,732,000
38,107,000
29,553,000
35,224,000
27,747,000
69,789,000
cash flow from investments
-27,452,000
8,270,000
27,911,000
-39,377,000
14,248,000
-12,753,000
-21,321,000
-23,525,000
-39,119,000
-4,213,000
-21,732,000
-38,107,000
-29,553,000
-35,224,000
-27,747,000
-69,789,000
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-2,484,000
-4,399,000
-3,058,000
10,462,000
2,746,000
2,442,000
-19,426,000
19,964,000
4,815,000
5,611,000
671,000
2,328,000
-14,396,000
13,537,000
-883,000
1,853,000
share issue
26,375,000
1,309,000
-28,323,000
-14,270,000
11,011,000
8,238,000
12,287,000
37,106,000
5,804,000
12,672,000
13,644,000
6,827,000
-1,135,000
4,781,000
53,770,000
interest
cash flow from financing
23,891,000
-3,090,000
-31,381,000
10,462,000
-11,524,000
13,453,000
-11,188,000
32,251,000
41,921,000
11,415,000
13,343,000
15,972,000
-7,569,000
12,402,000
3,898,000
55,623,000
cash and cash equivalents
cash
286,000
-377,000
-1,298,000
1,189,000
851,000
-2,796,000
1,415,000
-2,669,000
4,030,000
-1,277,000
1,944,000
-5,670,000
-7,786,000
-10,804,000
4,063,000
20,605,000
overdraft
change in cash
286,000
-377,000
-1,298,000
1,189,000
851,000
-2,796,000
1,415,000
-2,669,000
4,030,000
-1,277,000
1,944,000
-5,670,000
-7,786,000
-10,804,000
4,063,000
20,605,000
the kennedy trust for rheumatology research Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for the kennedy trust for rheumatology research. Get real-time insights into the kennedy trust for rheumatology research's credit score, group structure and payment trends.
The Kennedy Trust For Rheumatology Research Competitor Analysis
Perform a competitor analysis for the kennedy trust for rheumatology research by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mid companies, companies in EC1M area or any other competitors across 12 key performance metrics.
the kennedy trust for rheumatology research Ownership
THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH group structure
The Kennedy Trust For Rheumatology Research has no subsidiary companies.
Ultimate parent company
THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH
00963832
THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH Shareholders
The sole shareholder of The Kennedy Trust For Rheumatology Research is -.
-
-
the kennedy trust for rheumatology research directors
The Kennedy Trust For Rheumatology Research currently has 13 directors.
The longest serving directors include
Professor Stephen Holgate (Mar 2013) and
Mr Mark Dighero (Dec 2018).
the kennedy trust for rheumatology research Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to the kennedy trust for rheumatology research. Currently there are 1 open charges and 0 have been satisfied in the past.
the kennedy trust for rheumatology research Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH. This can take several minutes, an email will notify you when this has completed.
the kennedy trust for rheumatology researchCompanies House Filings - See Documents
